Charles F. Wagner Jr. - 01 Feb 2022 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Signature
/s/ Sabrina Yohai, Attorney-in-Fact
Issuer symbol
VRTX
Transactions as of
01 Feb 2022
Net transactions value
-$736,206
Form type
4
Filing time
03 Feb 2022, 15:29:28 UTC
Next filing
14 Feb 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Award $0 +3,698 +11% $0.000000 38,489 01 Feb 2022 Direct F1
transaction VRTX Common Stock Award $0 +11,628 +30% $0.000000 50,117 01 Feb 2022 Direct F2
transaction VRTX Common Stock Award $0 +10,262 +20% $0.000000 60,379 01 Feb 2022 Direct F3
transaction VRTX Common Stock Sale $736,206 -2,944 -4.9% $250.07 57,435 02 Feb 2022 Direct F4, F5, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents earned performance shares with respect to a performance stock unit award granted on 04/10/2019 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest on 02/24/2022.
F2 Represents earned performance shares with respect to a performance stock unit award granted on 02/03/2021 that contained performance-vesting requirements. The issuer's management development and compensation committee certified as to the level of performance-goal attainment on 02/01/2022 and the shares will vest in installments beginning on 02/17/2022.
F3 Restricted stock unit award that vests in installments beginning on 02/24/2023.
F4 Transaction made pursuant to Mr. Wagner's company approved trading plan under Rule 10b5-1.
F5 Open market sales reported on this line occurred at a weighted average price of $250.07 (range $250.00 to $250.09).
F6 Mr. Wagner undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.

Remarks:

Exhibit 24 - Power of Attorney